Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL17102914 | 0.97 | TSHR (0.37) | TSHRCYP2C19 | |
| Sulfuric Acid SCHEMBL16343941 | 0.94 | TSHR (0.33) | TSHRCYP2C19 | |
| Trifluoromethanesulfonic Acid SCHEMBL6742949 | 0.79 | CA1 (0.31) | — | |
| Hydrochloric Acid SCHEMBL26112378 | 0.78 | TSHR (0.41) | TSHRCYP2C19 | |
| Cyclohexane SCHEMBL732752 | 0.78 | TSHR (0.38) | TSHRCYP2C19 | |
| SCHEMBL261336 | 0.78 | TSHR (0.38) | TSHRCYP2C19 | |
| SCHEMBL20291779 | 0.78 | TSHR (0.38) | TSHRCYP2C19 | |
| SCHEMBL8672905 | 0.78 | TSHR (0.38) | TSHRCYP2C19 | |
| SCHEMBL1325359 | 0.78 | TSHR (0.38) | TSHRCYP2C19 | |
| SCHEMBL20198650 | 0.78 | TSHR (0.38) | TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160256481-A1 | USE OF WATER SOLUBLE PLATINUM COMPLEX IN PREPARING DRUGS FOR PREVENTION AND TREATMENT OF CANCERS | GUDUI BIOPHARMA TECHNOLOGY INC. (CN) | 2016-09-08 | — | — | US | disclosed |
| US-20150051387-A1 | WATER SOLUBLE PLATINUM COMPLEXES FOR TUMOR TREATMENT AND PROCESS OF PREPARING SAME | GUDUI BIOPHARMA TECHNOLOGY INC. (CN) | 2015-02-19 | — | — | US | disclosed |
| US-20150011740-A1 | FLUORINE-CONTAINING WATER SOLUBLE PLATINUM COMPLEXES FOR TUMOR TREATMENT AND PROCESS OF PREPARING SAME | GUDUI BIOPHARMA TECHNOLOGY INC. (CN) | 2015-01-08 | — | — | US | disclosed |
| US-7208611-B2 | Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use | XENOPORT, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060205677-A1 | Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use | XENOPORT, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051387-A1 | WATER SOLUBLE PLATINUM COMPLEXES FOR TUMOR TREATMENT AND PROCESS OF PREPARING SAME | TP53, GOT1, PDCD2L | TSHR 4366/4885CYP2C19 1016/4885 |
| US-20150011740-A1 | FLUORINE-CONTAINING WATER SOLUBLE PLATINUM COMPLEXES FOR TUMOR TREATMENT AND PROCESS OF PREPARING SAME | FOLR1, FOLR2, SLC46A1 | TSHR 2709/4885CYP2C19 796/4885 |
| US-20060205677-A1 | Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use | TYMP, TOP1, TOP2A | TSHR 4292/4885CYP2C19 4069/4885 |
| US-20160256481-A1 | USE OF WATER SOLUBLE PLATINUM COMPLEX IN PREPARING DRUGS FOR PREVENTION AND TREATMENT OF CANCERS | BRCA1, MCL1, TP53 | TSHR 3775/4885CYP2C19 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.